Last reviewed · How we verify
Wheat OIT
At a glance
| Generic name | Wheat OIT |
|---|---|
| Also known as | Vital Wheat Gluten |
| Sponsor | Hugh A Sampson, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (PHASE3)
- Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy (NA)
- ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (PHASE1, PHASE2)
- Open-label Extension Study of ADP101 (PHASE1, PHASE2)
- Oral Immunotherapy for Wheat Allergy (PHASE1, PHASE2)
- Multi OIT to Test Immune Markers After Minimum Maintenance Dose (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wheat OIT CI brief — competitive landscape report
- Wheat OIT updates RSS · CI watch RSS
- Hugh A Sampson, MD portfolio CI